Antibacterial monoclonal antibodies: The next generation?

Current Opinion in Microbiology

Volumn 27, Issue , 2015, Pages 78-85

  DiGiandomenico, Antonio ^a   Sellman, Bret R ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BACTERIAL CLEARANCE; BACTERIAL INFECTION; CROSS RESISTANCE; ESCHERICHIA COLI; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMONAS AERUGINOSA; REVIEW; BACTERIAL INFECTIONS; BACTERIUM; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BACTERIA; BACTERIAL INFECTIONS; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIOTA;

EID: 84939511930     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2015.07.014     Document Type: Review

References (53)

1. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013, 12:371-387.
2. Modi S.R., Collins J.J., Relman D.A. Antibiotics and the gut microbiota. J Clin Invest 2014, 124:4212-4218.
3. Cox L.M., Blaser M.J. Antibiotics in early life and obesity. Nat Rev Endocrinol 2014, 3:182-190.
4. Theriot C.M., Koenigsknecht M.J., Carlson P.E., Hatton G.E., Nelson A.M., Li B., Huffnagle G.B., Li J.Z., Young V.B. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 2014, 5:3114.
5. Leslie J.L., Young V.B. The rest of the story: the microbiome and gastrointestinal infections. Curr Opin Microbiol 2015, 23C:121-125.
6. Spellberg B., Rex J.H. The value of single-pathogen antibacterial agents. Nat Rev Drug Discov 2013, 12:963-c1.
7. Spellberg B., Shlaes D. Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 2014, 96:151-153.
8. Park W.H. Serum therapy. Bull N Y Acad Med 1931, 7:401-411.
9. Wagner K.S., Stickings P., White J.M., Neal S., Crowcroft N.S., Sesardic D., Efstratiou A. A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use. Vaccine 2009, 28:14-20.
10. Arnon S.S., Schechter R., Maslanka S.E., Jewell N.P., Hatheway C.L. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006, 354:462-471.
11. Reichert J.M. Antibodies to watch in 2015. MAbs 2015, 7:1-8.
12. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010, 9:767-774.
13. Nixon A.E., Sexton D.J., Ladner R.C. Drugs derived from phage display: from candidate identification to clinical practice. MAbs 2014, 6:73-85.
14. Lloyd C., Lowe D., Edwards B., Welsh F., Dilks T., Hardman C., Vaughan T. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 2009, 22:159-168.
15. Green L.L. Transgenic mouse strains as platforms for the successful discovery and development of human therapeutic monoclonal antibodies. Curr Drug Discov Technol 2014, 11:74-84.
16. Murphy E., Lin S.L., Nunez L., Andrew L., Fink P.S., Dilts D.A., Hoiseth S.K., Jansen K.U., Anderson A.S. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum Vaccin 2011, 7(Suppl.):51-59.
17. Horn M.P., Zuercher A.W., Imboden M.A., Rudolf M.P., Lazar H., Wu H., Hoiby N., Fas S.C., Lang A.B. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother 2010, 54:2338-2344.
18. Digiandomenico A., Warrener P., Hamilton M., Guillard S., Ravn P., Minter R., Camara M.M., Venkatraman V., Macgill R.S., Lin J., et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 2012, 209:1273-1287.
19. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., Santos C., Luke C.J., Torres-Velez F.J., Temperton N.J., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120:1663-1673.
20. Plosker G.L. 13-Valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr Drugs 2013, 15:403-423.
21. Jackson C., Mann A., Mangtani P., Fine P. Effectiveness of Haemophilus influenzae type b vaccines administered according to various schedules: systematic review and meta-analysis of observational data. Pediatr Infect Dis J 2013, 32:1261-1269.
22. Kelly-Quintos C., Cavacini L.A., Posner M.R., Goldmann D., Pier G.B. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect Immun 2006, 74:2742-2750.
23. Hazenbos W.L., Kajihara K.K., Vandlen R., Morisaki J.H., Lehar S.M., Kwakkenbos M.J., Beaumont T., Bakker A.Q., Phung Q., Swem L.R., et al. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog 2013, 9:e1003653.
24. Varrone J.J., de Mesy Bentley K.L., Bello-Irizarry S.N., Nishitani K., Mack S., Hunter J.G., Kates S.L., Daiss J.L., Schwarz E.M. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters. J Orthop Res 2014, 32:1389-1396.
25. Que Y.A., Lazar H., Wolff M., Francois B., Laterre P.F., Mercier E., Garbino J., Pagani J.L., Revelly J.P., Mus E., et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 2014, 33:1861-1867.
26. Lu Q., Eggimann P., Luyt C.E., Wolff M., Tamm M., Francois B., Mercier E., Garbino J., Laterre P.F., Koch H., et al. Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes. Crit Care 2014, 18:R17.
27. Baer M., Sawa T., Flynn P., Luehrsen K., Martinez D., Wiener-Kronish J.P., Yarranton G., Bebbington C. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009, 77:1083-1090.
28. Frank D.W., Vallis A., Wiener-Kronish J.P., Roy-Burman A., Spack E.G., Mullaney B.P., Megdoud M., Marks J.D., Fritz R., Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002, 186:64-73.
29. Francois B., Luyt C.E., Dugard A., Wolff M., Diehl J.L., Jaber S., Forel J.M., Garot D., Kipnis E., Mebazaa A., et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012, 40:2320-2326.
30. DiGiandomenico A., Keller A.E., Gao C., Rainey G.J., Warrener P., Camara M.M., Bonnell J., Fleming R., Bezabeh B., Dimasi N., et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 2014, 6:262ra155.
31. Murphy A.J., Macdonald L.E., Stevens S., Karow M., Dore A.T., Pobursky K., Huang T.T., Poueymirou W.T., Esau L., Meola M., et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014, 111:5153-5158.
32. Warrener P., Varkey R., Bonnell J.C., DiGiandomenico A., Camara M., Cook K., Peng L., Zha J., Chowdury P., Sellman B., Stover C.K. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother 2014, 58:4384-4391.
33. Babcock G.J., Broering T.J., Hernandez H.J., Mandell R.B., Donahue K., Boatright N., Stack A.M., Lowy I., Graziano R., Molrine D., et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006, 74:6339-6347.
34. Lowy I., Molrine D.C., Leav B.A., Blair B.M., Baxter R., Gerding D.N., Nichol G., Thomas W.D., Leney M., Sloan S., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
35. Foletti D., Strop P., Shaughnessy L., Hasa-Moreno A., Casas M.G., Russell M., Bee C., Wu S., Pham A., Zeng Z., et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol 2013, 425:1641-1654.
36. Tkaczyk C., Hua L., Varkey R., Shi Y., Dettinger L., Woods R., Barnes A., MacGill R.S., Wilson S., Chowdhury P., et al. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 2012, 19:377-385.
37. Ragle B.E., Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 2009, 77:2712-2718.
38. Berube B.J., Bubeck Wardenburg J. Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins (Basel) 2013, 5:1140-1166.
39. Hua L., Hilliard J.J., Shi Y., Tkaczyk C., Cheng L.I., Yu X., Datta V., Ren S., Feng H., Zinsou R., et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 2014, 58:1108-1117.
40. Tkaczyk C., Hamilton M.M., Datta V., Yang X.P., Hilliard J.J., Stephens G.L., Sadowska A., Hua L., O'Day T., Suzich J., et al. Alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLOS ONE 2013, 8:e75103.
41. Oganesyan V., Peng L., Damschroder M.M., Cheng L., Sadowska A., Tkaczyk C., Sellman B.R., Wu H., Dall'Acqua W.F. Mechanisms of neutralization of a human anti-alpha toxin antibody. J Biol Chem 2014, 289:29874-29880.
42. Robbie G.J., Criste R., Dall'acqua W.F., Jensen K., Patel N.K., Losonsky G.A., Griffin M.P. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013, 57:6147-6153.
43. Rouha H., Badarau A., Visram Z.C., Battles M.B., Prinz B., Magyarics Z., Nagy G., Mirkina I., Stulik L., Zerbs M., et al. Five birds, one stone: neutralization of alpha-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 2015, 7:243-254.
44. Bergen P.J., Bulman Z.P., Saju S., Bulitta J.B., Landersdorfer C., Forrest A., Li J., Nation R.L., Tsuji B.T. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 2015, 35:34-42.
45. Migone T.S., Bolmer S., Zhong J., Corey A., Vasconcelos D., Buccellato M., Meister G. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. Antimicrob Agents Chemother 2015, 59:1145-1151.
46. Hilliard J.J., Datta V., Tkaczyk C., Hamilton M., Sadowska A., Jones-Nelson O., O'Day T., Weiss W.J., Szarka S., Nguyen V., et al. Anti-alpha toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother 2014, 59:299-309.
47. Varshney A.K., Wang X., MacIntyre J., Zollner R.S., Kelleher K., Kovalenko O.V., Pechuan X., Byrne F.R., Fries B.C. Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin. J Infect Dis 2014, 210:973-981.
48. Song Y., Baer M., Srinivasan R., Lima J., Yarranton G., Bebbington C., Lynch S.V. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis 2012, 31:1837-1845.
49. Biron B., Beck K., Dyer D., Mattix M., Twenhafel N., Nalca A. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother 2015, 59:2206-2214.
50. Secher T., Fas S., Fauconnier L., Mathieu M., Rutschi O., Ryffel B., Rudolf M. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLOS ONE 2013, 8:e73396.
51. Karauzum H., Chen G., Abaandou L., Mahmoudieh M., Boroun A.R., Shulenin S., Devi V.S., Stavale E., Warfield K.L., Zeitlin L., et al. Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome. J Biol Chem 2012, 287:25203-25215.
52. Yang Z., Ramsey J., Hamza T., Zhang Y., Li S., Yfantis H.G., Lee D., Hernandez L.D., Seghezzi W., Furneisen J.M., et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun 2015, 83:822-831.
53. Bitzan M., Poole R., Mehran M., Sicard E., Brockus C., Thuning-Roberson C., Riviere M. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 2009, 53:3081-3087.